Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors
October 05 2021 - 8:00AM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric
medicine company commercializing the CellFX® System powered by
Nano-Pulse Stimulation™ (NPS™) technology, today announced the
appointment of Laureen DeBuono to its Board of Directors.
Concurrent to Ms. DeBuono’s appointment, Kenneth Clark has resigned
from the Board of Directors.
“We are delighted and honored to welcome Laureen to the Pulse
Biosciences Board,” said Robert Duggan, Chairman of the Pulse
Biosciences Board of Directors. “Laureen is an accomplished
executive with a track record of driving growth and creating
shareholder value through operational, financial and strategic
execution for multiple life sciences, medical technology, and
aesthetics companies. We look forward to her insight as we grow the
CellFX System’s commercial footprint in dermatology and further
expand as a multi-specialty bioelectric medicine company. We also
want to thank Ken for his four years of exemplary service and
guidance. His steadfast support and indelible surge to pursue
success has inspired all Pulse Biosciences’ stakeholders. Rest
assured, we will undoubtably use his willingness to consult with us
in the future.”
Ms. DeBuono currently serves as a Managing Partner at FLG
Partners LLC, the leading interim executive and Board advisory firm
in Silicon Valley, which she joined in 2011. As an Advisor to the
Board of Directors and Interim CFO, she helped lead the growth of
Rodan+Fields, a premium skincare company with a unique sales
business model between 2014 and 2016. Most recently she also served
as CEO and Board Member of govino, LLC, a global CPG company from
2018 through January 2020. Also in 2018, Ms. DeBuono joined
HotelTonight as a Board Advisor and Interim CFO, to advise and
oversee its sale to AirBnB in April 2019. Previously, Ms. DeBuono
served in various executive capacities at multiple healthcare,
medical technology and CPG companies from 1992-2017.
Ms. DeBuono received a BA from Duke University, an MA from
Stanford University, and a JD from the New York University School
of Law. Ms. DeBuono is a member of the State Bar of California. She
has also attended the Stanford Directors’ College and is a
certified Board Leadership Fellow with the National Association of
Corporate Directors.
“What attracted me to Pulse Biosciences is the diverse
opportunity set for Nano-Pulse Stimulation technology and the
experienced leadership team,” said Laureen DeBuono, Director, Pulse
Biosciences. “There is great potential for this platform and I am
excited to leverage my past experiences with growth companies to
help Pulse Biosciences scale operationally, financially and
strategically.”
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nano-Pulse Stimulation™ (NPS™) technology delivers nano-second
pulses of electrical energy to non-thermally clear cells while
sparing adjacent non-cellular tissue. The CellFX® System is the
first commercial product to harness the distinctive advantages of
NPS technology to treat a variety of applications for which an
optimal solution remains unfulfilled. The initial commercial use of
the CellFX System is to address a range of dermatologic conditions
that share high demand among patients and practitioners for
improved dermatologic outcomes. Designed as a multi-application
platform, the CellFX System offers customer value with a
utilization-based revenue model. Visit pulsebiosciences.com to
learn more.
To stay informed about the CellFX System, please visit
CellFX.com and sign-up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the
stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211005005394/en/
Investors: Pulse Biosciences Sandra Gardiner, EVP and CFO
510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip
Taylor 415.937.5406 philip@gilmartinir.com
Media: Tosk Communications Nadine D. Tosk 504.453.8344
nadinepr@gmail.com or press@pulsebiosciences.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024